Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Researchers sought to determine whether pediatric patients with CML may have attenuated growth when receiving treatment with nilotinib.
Researchers sought to determine the risk factors of CNS relapse in pediatric patients with ALL.
Researchers sought to determine whether patients with B-ALL who progress after CAR-T therapy would have a poor prognosis.
Researchers sought to determine whether the ALFA decision tool would be able to determine the prognosis for older patients with AML treated with intensive chemotherapy.
Researchers sought to determine whether CD-70 targeting CAR-T therapy would be an effective therapeutic strategy in patients with AML.
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Researchers sought to determine whether the antisense oligonucleotide oblimersen can be added safely to conventional chemotherapy for older patients with AML.
Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.
Researchers sought to determine whether for CD200 expression in leukemia stem cells would be associated with acute myeloid leukemia and therefore be a target for treatment.
Researchers sought to determine the efficacy of the COVID-19 vaccine in patients with CLL.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Researchers sought to determine whether CXCL12 expression would be a predictor of poor prognosis in patients with acute myeloid leukemia.
Researchers seek to characterize adherence trajectories, determine how side effects or financial status influence adherence, assess how adherence effects clinical outcomes, and explore unique patient perspectives.
Experts outline treatment options for patients with venetoclax resistance.
Researchers sought to determine whether activation of MAPK pathway genes may play a role in resistance to PI3K inhibitor therapy in patients with CLL.
A retrospective analysis sought to determine if adding leukapheresis would improve survival in AML patients with leukostasis.
Researchers sought to update the latest information about cytogenetics in pediatric patients with AML with a focus on de novo disease.
Researchers sought to determine the characteristic differences between LR and VLR in patients with ALL.
Researchers sought to determine the role of PML in glioblastoma and whether this may be a therapeutic target.
Acute myeloid leukemia (AML) progresses more rapidly than other forms of leukemia. As such, if you or your patient are concerned they may have AML it is important to educate them on the symptoms and risk factors of the disease, as well as how to detect it and what treatments it could entail.
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
At 4 years, there was no significant difference in overall survival.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
A retrospective study demonstrates that TKI therapy discontinuation occurs frequently and successfully both in clinical trials and in the general population.
Researchers sought to determine whether JAK1 inhibition would be a therapeutic target in patients with AF10-rearranged acute myeloid leukemia.
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.
Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.
Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.
The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.
Researchers sought to determine what genetic mutations may have prognostic significance for chemotherapy and stem cell transplant in patients with AML.
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
Researchers sought to determine whether leukemia-specific T-cells would be a safe treatment for patients with AML or MDS after HSCT.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
The 12-month overall survival rate was 88%.
IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
Researchers sought to identify a new model for predicting survival in patients with with acute myeloid leukemia.
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Researchers sought to determine whether epigenetic mutations may affect AML outcomes in elderly patients, and how that can inform use of decitabine-based regimens.